Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study

Hepatology

Volumn 36, Issue 4I, 2002, Pages 949-958

  Heemann, Uwe ^a   Treichel, Ulrich ^a   Loock, Jan ^a   Philipp, Thomas ^a   Gerken, Guido ^a   Malago, Massimo ^a   Klammt, Sebastian ^b   Loehr, Matthias ^b   Liebe, Stephan ^b   Mitzner, Steffen ^b   Schmidt, Reinhardt ^b   Stange, Jan ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILE ACID; BILIRUBIN; CHARCOAL;

ADULT; AGED; ANION EXCHANGE; ARTICLE; ARTIFICIAL KIDNEY; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DIALYSIS; FEMALE; HEPATIC ENCEPHALOPATHY; HOLLOW FIBER; HUMAN; HYPERBILIRUBINEMIA; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER INJURY; MALE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; SURVIVAL;

ADULT; FEMALE; HUMANS; HYPERBILIRUBINEMIA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; RENAL DIALYSIS; SERUM ALBUMIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036789336     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36130     Document Type: Article

References (25)

1. Bonn D. Hybrid devices offer hope for the failing liver. Lancet 1996;348:1372.
2. Editorial. Progress with an artificial liver. Lancet 1974;2:992-994.
3. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971;2:75-80.
4. Green J, Better OS. Systemic hypotension and renal failure in obstructive jaundice-mechanistic and therapeutic aspects. J Am Soc Nephrol 1995;5:1853-1871.
5. Inan M, Sayek I, Tel BC, Sahin-ErdemLi I. Role of endotoxin and nitric oxide in the pathogenesis of renal failure in obstructive jaundice. Br J Surg 1997;84:943-947.
6. Utkan ZN, Sarioglu Y, Gonullu NN. Effects of experimental obstructive jaundice on contractile responses of dog isolated blood vessels: role of endothelium and duration of bile duct ligation. Clin Exp Pharmacol Physiol 2000;27:339-344.
7. Clements WD, McCaigue M, Erwin P, Halliday I, Rowlands BJ. Biliary decompression promotes Kupffer cell recovery in obstructive jaundice. Gut 1996;38:925-931.
8. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999;103:137-145.
9. Stamler JS, Jaraki O, Osborne J, Simon D, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an s-nitroso adduct of serum albumin. Proc Natl Acad Sci U S A 1992;89:7674-7677.
10. Kashiba-Iwatsuki M, Miyamoto M, Inoue M. Effect of nitric oxide on the ligand binding activity of albumin. Arch Biochem Biophys 1997;345:237-242.
11. Malchesky PS. Nonbiological liver support: historic overview. Artif Organs 1994;18:342-347.
12. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin bound toxins. Artif Organs 1993;17:809-813.
13. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-286.
14. Mohapatra MK, Samal MM, Padhiary KN, Dash PC, Sahoo GN, Pamaik BC. Clinicopathological profile ofsubacute hepatic failure. J Assoc Physicians India 1996;44:375-377.
15. Sano K, Kubota K, Bandai Y, Makuuchi M. Rate of bilirubin decrease as a risk predictor in hepato-biliary surgery. Hepatogastroenterology 1999;46:2171-2177.
16. Arroyo V, Gines P, Gerbes AL, DudLey FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-176.
17. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-sytemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978;23:398-406.
18. Child CG III. The Liver and Portal Hypertension. Philadelphia, PA, Saunders, 1964, p 50.
19. Pugh RNH. Transsection of the esophagus for bleeding esophageal varices. Brit J Surg 1973;60:646-649.
20. Stange J, Hassanein TI, Mehta R, Mitzner S, Battlett RH. The Molecular Adsorbents Recycling System (MARS) as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective randomized controlled clinical trials and clinical experience from 19 centers. Artif Organs 2002;26;103-110.
21. Schmidt LE, Sorensen VR, Svendsen LB, BA Hansen, Larsen FS. Hemodynamic changes during a single treatment with the Molecular Adsorbent Recirculating System in patients with acute on chronic liver failure. Liver Transpl 2001;7:1034-1039.
22. Sorkine P, Abraham RB, Szold O, Bidermann P, Kidron A, Merchav H, Brill S, et al. Role of the molecular adsorbents recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001;29:1332-1336.
23. Awad S, Swaniker F, Magee J, Punch J, Barrlett RH. Results of a phase 1 trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001;130:354-362.
24. Schmidt LE, Svendson LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001;7:709-712.
25. Seige M, Kreymann B, Jeschke B, Schweigart U, Kopp KF, Classen M: Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Transpl Proc 1999;31:1371-1375.